ESR1 and breast cancer: The expression of PD-L1 has been evaluated in a number of different tumor types including breast cancer.[5]–[7] Ghebeh et al. reported that PD-L1 expression was associated with a variety of adverse features such as higher grade, negative estrogen receptor status, and increased infiltration with T regulatory cells.